Endocrine treatment with letrozole achieved signif
Tamoxifen, an anti-estrogen preparation, used for the treatment of breast cancer since the 70's of the 20th century, was considered as a classical endocrine agent for breast cancer. However, a latest report showed that in the treatment of late stage breast cancer, letrozole, an aromatizing enzyme inhibitor, was much more significantly effective than tamoxifen to prolong the survival period of the patients.
According to the recommendation of Professor Song Sanqin of No. 307 Hospital of the army, this project with the code number of 025 was an assembly of multi-center, large scale, randomized, double blind study enrolled a total of 907 late recurrent cases with metastasis in 201 medical establishments of 29 countries; the patients were given respectively tamoxifen (453 cases) or letrozole (454 cases) as the first line treatment (48 cases from China joined the group). The primary endpoint was tumor progress period and the secondary endpoints were the period of treatment failure, the total effective rate and the total survival period etc.
The results showed that the median tumor progress period were respectively 9.4 months and 6.0 months for the letrozole and tamoxifen groups (P<0.0001). The period of treatment of the two groups were respectively 9.0 months and 5.7 months (P<0.0001). The median prolonged survival periods of the two groups were respectively 42 months and 30 months (P=0.011). There was no significant difference between these two agents in the aspects of side effects and the patients all tolerated the agents well., 百拇医药
According to the recommendation of Professor Song Sanqin of No. 307 Hospital of the army, this project with the code number of 025 was an assembly of multi-center, large scale, randomized, double blind study enrolled a total of 907 late recurrent cases with metastasis in 201 medical establishments of 29 countries; the patients were given respectively tamoxifen (453 cases) or letrozole (454 cases) as the first line treatment (48 cases from China joined the group). The primary endpoint was tumor progress period and the secondary endpoints were the period of treatment failure, the total effective rate and the total survival period etc.
The results showed that the median tumor progress period were respectively 9.4 months and 6.0 months for the letrozole and tamoxifen groups (P<0.0001). The period of treatment of the two groups were respectively 9.0 months and 5.7 months (P<0.0001). The median prolonged survival periods of the two groups were respectively 42 months and 30 months (P=0.011). There was no significant difference between these two agents in the aspects of side effects and the patients all tolerated the agents well., 百拇医药